Homologous human blood protein separation using immobilized metal affinity chromatography: Protein C separation from prothrombin with application to the separation of factor IX and prothrombin

被引:31
作者
Wu, HP [1 ]
Bruley, DF [1 ]
机构
[1] Univ Maryland Baltimore Cty, Dept Chem & Biochem Engn, Baltimore, MD 21250 USA
关键词
D O I
10.1021/bp9901015
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Protein C (PC) is a natural anticoagulant and antithrombotic present in human blood at a concentration of 4 mu g/mL. Its deficiency can result in excessive clotting and thrombosis. Protein C can be obtained from human blood plasma; however, there are other coagulant proteins in blood, including prothrombin (factor II), which is present in relatively large amounts and is one of the most active components. Protein C and prothrombin are homologous proteins with similar biochemical features; therefore, immunoaffinity chromatography is used for their separation. However, this technology is very expensive, protein C recovery and activity is low, and contamination problems with mouse antibody are likely. Immobilized metal affinity chromatography (IMAC) utilizes the protein metal-binding properties for protein separation. Protein C has twelve surface-accessible histidines, which are the major metal-binding groups for IMAC separation. After investigating metal ion-binding properties of protein C, we used an IDA-Cu column to separate protein C and prothrombin. Following protein adsorption to the column, prothrombin was washed out using a sodium phosphate buffer containing 2 mM imidazole and protein C was recovered with 15 mM imidazole in the buffer. The mild elution condition allows a high protein C activity and a high recovery. Also, this technology introduces no immunoglobulins, and it is relatively inexpensive. IMAC could replace the immunoaffinity technology for the large-scale separation of protein C from blood plasma Cohn Fraction IV-1. In addition, this work demonstrates a significant application of this technology for the separation of factor IX from prothrombin. Prothrombin has proven to be a harmful contaminant in factor TX cocktails that have been administered to humans in the treatment of hemophilia B.
引用
收藏
页码:928 / 931
页数:4
相关论文
共 16 条
  • [1] BRULEY DF, 1990, ADV APPL BIOTECHNOLO, V11, P11
  • [2] ESMON CT, 1989, J BIOL CHEM, V264, P4743
  • [3] FULCHER CA, 1984, BLOOD, V63, P486
  • [4] JOHNSON AE, 1983, J BIOL CHEM, V258, P5554
  • [5] THROMBOEMBOLIC COMPLICATIONS
    KASPER, CK
    [J]. THROMBOSIS ET DIATHESIS HAEMORRHAGICA, 1975, 33 (03): : 640 - 644
  • [6] CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4
    LAEMMLI, UK
    [J]. NATURE, 1970, 227 (5259) : 680 - +
  • [7] MENACHE D, 1984, BLOOD, V64, P1220
  • [8] MENACHE D, 1975, BRIT J HAEMATOLOGY S, V31, P247
  • [9] MENACHE D, 1980, TREATMENT BLEEDING D, V1, P183
  • [10] ODEGAARD OR, 1987, HAEMOSTASIS, V17, P109